RxDoctor Payments Data

Mark Pinto, MD

Internal Medicine · Fresno, CANPI 1801882360

Payments from drug & device makers

$591in general payments, 2019–2025

Across 31 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$87
  • Lilly USA, LLC$64
  • Biohaven Pharmaceutical Holding Company Ltd.$61
  • Sanofi Pasteur Inc.$44
  • Amgen$42
  • Novo Nordisk$37
  • plus $255 from 12 others

What the payments were for

  • Food & beverage$591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$591 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$687
Medicare patients
26
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$40,044
JardianceEmpagliflozin45$34,941
TrulicityDulaglutide31$31,176
EliquisApixaban28$22,500
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$18,178
JanuviaSitagliptin Phosphate21$15,083
FarxigaDapagliflozin Propanediol14$13,651
Breo ElliptaFluticasone/Vilanterol29$12,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,415
Arnuity ElliptaFluticasone Furoate24$5,116
Albuterol Sulfate HfaAlbuterol Sulfate115$4,450
Fluticasone Propionate HfaFluticasone Propionate11$2,802
Atorvastatin Calcium411$2,750
Aripiprazole14$2,377
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$40,04433 claims
Lilly USA, LLCTrulicity$64$31,17631 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$28$28,52267 claims
PfizerEliquis$21$22,50028 claims
MerckJanuvia$36$15,08321 claims
AstraZenecaFarxiga$31$13,65114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →